Tag: Cordis

Cordis promotes Alan Tsai as GM Greater China

SHANGHAI, Nov. 7, 2022 /PRNewswire/ — From November 1, 2022, Mr. Alan Tsai is promoted to the role of General Manager of Cordis Greater China. He will head the leadership team responsible for strategic planning, business operation and team development for Greater China, the fastest growing area in Asia Pacific. Based in Shanghai, he will report directly to Bryan […]

Cordis Announces Acquisition of MedAlliance, Positioning Itself for Market Leadership in Drug-Eluting Balloon Technology

MIAMI LAKES, Fla., Oct. 18, 2022 /PRNewswire/ — Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technologies, today announced its acquisition, subject to customary closing conditions including regulatory approvals, of MedAlliance, a Switzerland-based company at the forefront of transformative drug-eluting balloons. By acquiring MedAlliance, Cordis has the potential to […]

Cordis Announces Start of Enrollment in RADIANCY Clinical Study in Europe

Multi-center study to evaluate safety and efficacy of S.M.A.R.T. RADIANZ™ Vascular Stent System via Radial Access MIAMI LAKES, Fla., July 14, 2022 /PRNewswire/ — Cordis, a global leader in cardiovascular technologies, today announced the start of the RADIANCY pre-market clinical study in Europe. It is a prospective, multi-center, single-arm study to assess the […]

Cordis Announces Successful First-in-Human Use of the Radianz Radial Peripheral System™

Successful procedures initiate U.S. limited market release MIAMI LAKES, Fla., June 16, 2022 /PRNewswire/ — Cordis, a global leader in cardiovascular technologies, today announced the first-in-human use of the Radianz Radial Peripheral System™ by Jihad Mustapha, MD, FACC, FSCAI at Advanced Cardiac & Vascular Centers (ACV) in Grand Rapids, Michigan. The Radianz Radial Peripheral System™ solution […]

ENDOVASCULAR ENGINEERING SECURES $15 MILLION SERIES A1 FINANCING FOR VENOUS THROMBECTOMY SOLUTIONS

MENLO PARK, Calif., April 5, 2022 /PRNewswire/ — Endovascular Engineering (“E2”), a privately-held developer of next-generation thrombectomy devices to treat patients with Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), today announced the closing of a $15 million Series A1 financing. The financing was co-led by Santé Ventures and Cordis, who were joined by […]

S.M.A.R.T. RADIANZ™ Vascular Stent System Approved for Transradial Use in the U.S.

Completes the RADIANZ Radial Peripheral System™; signals Cordis’ renewed investment in innovation MIAMI LAKES, Fla., March 10, 2022 /PRNewswire/ — Cordis, a global cardiovascular technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the S.M.A.R.T. RADIANZ™ Vascular Stent System, a self-expanding stent purposefully engineered for radial peripheral procedures. […]

CORDIS NAMES CHRISTOPHER SCULLY TO CFO POST

Cordis continues leadership team buildout with seasoned healthcare finance officer MIAMI LAKES, Fla., Dec. 16, 2021 /PRNewswire/ — Cordis, a global interventional cardiovascular technology company, today announced that Christopher Scully has joined the organization as Chief Financial Officer. He will be responsible for leading the company’s financial and IT functions and will play an instrumental […]

Cordis Names George Adams, MD as Chief Medical Officer

Globally recognized interventional cardiologist is the latest addition to a growing leadership team MIAMI LAKES, Fla., Dec. 9, 2021 /PRNewswire/ — Cordis, a global cardiovascular technology company, today announced George Adams, MD, MHS, MBA, FACC, FSCAI as Chief Medical Officer, furthering the organization’s mission to differentiate itself as a technological leader and value-based […]

Cardinal Health completes sale of Cordis business to Hellman & Friedman

DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health’s Cordis business to H&F. The sale price of approximately $1 billion includes the buyer’s assumption of certain liabilities and the seller’s retention of certain working capital accounts. […]